Effects of the endogenous PPAR-α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice

Synapse

Volumn 64, Issue 5, 2010, Pages 379-389

  Plaza Zabala, Ainhoa ^a   Berrendero, Fernando ^a   Suarez, Juan ^b   Bermudez Silva, Francisco Javier ^b   Fernandez Espejo, Emilio ^c   Serrano, Antonia ^d   Pavon, Francisco Javier ^d   Parsons, Loren H ^d   De Fonseca, Fernando Rodriguez ^b   Maldonado, Rafael ^a   Robledo, Patricia ^a,e  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b Hospital University Carlos Haya de Málaga   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Active avoidance; DAT; Ecstasy; OEA; Recall; TH

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE TRANSPORTER; N OLEOYLETHANOLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BINDING SITE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LEARNING; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TASK PERFORMANCE;

ANIMALS; AVOIDANCE LEARNING; COGNITION DISORDERS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; MENTAL RECALL; MESENCEPHALON; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOOTROPIC AGENTS; OLEIC ACIDS; PPAR ALPHA; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 73449147663     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20733     Document Type: Article

References (49)

1. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB. 1987. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916.
2. Berdyshev EV, Schmid PC, Dong Z, Schmid HH. 2000. Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem J 346:369-374.
3. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M. 2006. PPAR: A new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341-1346.
4. Burrows KB, Gudelsky G, Yamamoto BK. 2000. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4- methylenedioxymethamphetamine administration. Eur J Pharmacol 398:11-18.
5. Cadet JL, Thiriet N, Jayanthi S. 2001. Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Int (Paris) 152:IS57-IS59.
6. Cadet JL, Drasnova IN, Jayanthi S, Lyles J. 2007. Neurotoxicity of substituted amphetamines: Molecular and cellular mechanisms. Neurotox Res 11:183-202.
7. Callahan BT, Cord BJ, Ricaurte GA. 2001. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40:113-121.
8. Capela JP, Meisel A, Abreu AR, Branco PS, Ferreira LM, Lobo AM, Remião F, Bastos ML, Carvalho F. 2006. Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J Pharmacol Exp Ther 316:53-61.
9. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR. 2001. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol 134:1711-1723.
10. Cole JC, Sumnall HR. 2003. The pre-clinical behavioral pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27:199-217.
11. Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. 2003. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271.
12. Farioli-Vecchioli S, Moreno S, Ceru7grave; MP. 2001. Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system. J Neurocytol 30:21-33.
13. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425:90-93.
14. Galan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo E. 2009. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology 56:653-664.
15. González-Yanes C, Serrano A, Bermúdez-Silva FJ, Hernández-Dominguez M, Páez-Ochoa MA, Rodríguez de Fonseca F, Sánchez-Margalet V. 2005. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 289:E923-E929.
16. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. 2003. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27:819-827.
17. Hiramatsu M, Kumagai Y, Unger SE, Cho AK. 1990. Metabolism of methylenedioxymethamphetamine: Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-527.
18. Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M, Komoda T, Katayama S. 1998. Bezafibrate has an antioxidant effect: Peroxisome proliferator-activated receptor alpha is associated with Cu2+. Zn2+-superoxide dismutase in the liver. Life Sci 63:135-144.
19. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50:3-11.
20. Ludewig S, Ludewig K, Hasler F, Vollenweider FX. 2003. No lasting effects of moderate doses of MDMA (ecstasy) on memory performance and mood states in healthy humans. Biol Psychiatry 53:205S.
21. Lyvers M. 2006. Recreational ecstasy use and the neurotoxic potential of MDMA: Current status of the controversy and methodological issues. Drug Alcohol Rev 25:269-276.
22. Malberg JE, Seiden L. 1998. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18:5086-5094.
23. Monks TJ, Lau SS. 1997. Biological reactivity of polyphenolic-glutathione conjugates. Chem Res Toxicol 10:1296-1313.
24. Moreno S, Nardacci R, Cerù MP. 1997. Regional and ultrastructural immunolocalization of copper-zinc superoxide dismutase in rat central nervous system. J Histochem Cytochem 45:1611-1622.
25. Naranjo JR, Mellström B. 2007. Split personality of transcription factors inside and outside the nuclear border. Sci STKE 371:pe5.
26. Parrott AC. 2002. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837-844.
27. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K. 1998. Cognitive performance in recreational users of MDMA of 'ecstasy': Evidence for memory deficits. J Psychopharmacol 12:79-83.
28. Paxinos G, Franklin KBJ. 1997. The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
29. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, Fourth Edition. New York: Academic Press.
30. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
31. Piper BJ, Meyer JS. 2004. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79:723-731.
32. Poynter ME, Daynes RA. 1998. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-jB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841.
33. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW. 1988. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260:51-55.
34. Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D. 2001. An anorexic lipid mediator regulated by feeding. Nature 414:209-212.
35. Rosecrans JA, Glennon RA. 1987. The effect of MDA and MDMA ("ecstasy") isomers in combination with pirenpirone on operant responding in mice. Pharmacol Biochem Behav 28:39-42.
36. Ryan RE, Ross SA, Drago J, Loiacono RE. 2001. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 132: 1650-1656.
37. Sarne Y, Mechoulam R. 2005. Cannabinoids: Between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4:677-684.
38. Schäbitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D. 2002. Release of fatty acid amides in a patient with hemispheric stroke: A microdialysis study. Stroke 33:2112-2114.
39. Serrano A, Del Arco I, Pavón J, Macías M, Perez-Valero V, Rodríguez de Fonseca F. 2008a. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 54:226-234.
40. Serrano A, Pavon J, De Diego Y, Romero-Zerbo Y, Bermudez-Silva FJ, Bautista D, Mayas M, Rodriguez de Fonseca F, Macias-Gonzalez M. 2008b. Oleoylethanolamide, a ligand of the peroxisome proliferator-activated receptor alpha, prevents liver injury and oxidative stress induced by Tween 20. Obes Metabol 4:76-84.
41. Skelton MR, Williams MT, Vorhees CV. 2006. Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats. Psychopharmacology (Berl) 189:307-318.
42. Sprague JE, Nichols DE. 2005. Neurotoxicity of MDMA (ecstasy): Beyond metabolism. Trends Pharmacol Sci 26:59-60.
43. Stumm G, Schlegel J, Schafer T, Wurz C, Mennel HD, Krieg JC, Vedde H. 1999. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J 13:1065-1072.
44. Taffe MA, Weed MR, Davis S, Huitrón-Resendiz S, Schroeder R, Parsons LH, Henriksen SJ, Gold LH. 2001. Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology 24:230-239.
45. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM. 2004. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367:349-354.
46. Trigo JM, Cabrero-Castel A, Berrendero F, Maldonado R, Robledo P. 2008. MDMA modifies active avoidance learning and recall in mice. Psychopharmacology 197:391-400.
47. Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, Veldink GA, Vliegenthart JF, Bär PR, Nicolay K, Di Marzo V. 2003. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: Role of vanilloid receptors and lipoxygenases. J Neurosci 23:4127-4133.
48. Walter L, Franklin A, Witting A, Moller T, Stella N. 2002. Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277:20869-20876.
49. Yamamoto BK, Bankson MG. 2005. Amphetamine neurotoxicity: Cause and consequence of oxidative stress. Crit Rev Neurobiol 17:87-117.